These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 35713302)
21. Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation--4-year experience at a moderate-volume center. Jensen S; Jackson EC; Riley L; Reddy S; Goebel J Pediatr Transplant; 2003 Apr; 7(2):119-24. PubMed ID: 12654052 [TBL] [Abstract][Full Text] [Related]
22. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. Rhu J; Lee KW; Park H; Park JB; Kim SJ; Choi GS Ann Transplant; 2017 Nov; 22():707-718. PubMed ID: 29180612 [TBL] [Abstract][Full Text] [Related]
23. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288 [TBL] [Abstract][Full Text] [Related]
24. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753 [TBL] [Abstract][Full Text] [Related]
25. Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. Handisurya A; Kerscher C; Tura A; Herkner H; Payer BA; Mandorfer M; Werzowa J; Winnicki W; Reiberger T; Kautzky-Willer A; Pacini G; Säemann M; Schmidt A PLoS One; 2016; 11(1):e0145319. PubMed ID: 26735686 [TBL] [Abstract][Full Text] [Related]
26. Impact of Protease Inhibitor-Based Antiretroviral Therapy on Tacrolimus Intrapatient Variability in HIV-Positive Kidney Transplant Recipients. Cooper M; Dunne I; Kuten S; Curtis A; Graviss EA; Nguyen DT; Hobeika M; Gaber AO Transplant Proc; 2021 Apr; 53(3):984-988. PubMed ID: 33246588 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the characteristics of adult liver transplant recipients with prope (almost) tolerance and full immunosuppression regimen. Shamsaeefar A; Nikoupour H; Kazemi K; Gholami S; Moosavi SA; Motazedian N; Sayadi M; Afshinnia F; Nikeghbalian S; Malekhosseini SA Transpl Immunol; 2021 Oct; 68():101440. PubMed ID: 34343659 [TBL] [Abstract][Full Text] [Related]
29. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related]
30. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724 [TBL] [Abstract][Full Text] [Related]
31. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia. Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018 [TBL] [Abstract][Full Text] [Related]
32. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474 [No Abstract] [Full Text] [Related]
33. Tacrolimus: immunosuppression following liver and kidney transplant. Clark W J Clin Pharm Ther; 1996 Jun; 21(3):135-41. PubMed ID: 8873845 [TBL] [Abstract][Full Text] [Related]
34. Managing the significant interaction between XR tacrolimus and fluconazole in kidney transplant recipients. Lange NW; Hedvat J; Tsapepas DS; Salerno DM Clin Transplant; 2020 Aug; 34(8):e14001. PubMed ID: 32564404 [No Abstract] [Full Text] [Related]
35. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients. Ferraresso M; Ghio L; Edefonti A; Garavaglia R; Berardinelli L Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478 [TBL] [Abstract][Full Text] [Related]
36. Tacrolimus Concentration-to-Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes. Bartlett FE; Carthon CE; Hagopian JC; Horwedel TA; January SE; Malone A Pharmacotherapy; 2019 Aug; 39(8):827-836. PubMed ID: 31230376 [TBL] [Abstract][Full Text] [Related]
37. Induction immunosuppression in kidney transplant recipients with HIV: To deplete or not to deplete? Agrawal A; Stosor V Transpl Infect Dis; 2024 Aug; 26(4):e14299. PubMed ID: 38953433 [No Abstract] [Full Text] [Related]
38. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. Xenos EX; Ciancio G; Burke GW; Roth D; Miller J Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949 [TBL] [Abstract][Full Text] [Related]
39. Reducing Tacrolimus Levels to Improve Cognitive Function in Kidney Transplant Recipients. Bigotte Vieira M Kidney360; 2024 Jul; 5(7):936-937. PubMed ID: 39052471 [No Abstract] [Full Text] [Related]
40. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction. Gallo E; Abbasciano I; Mingozzi S; Lavacca A; Presta R; Bruno S; Deambrosis I; Barreca A; Romagnoli R; Mella A; Fop F; Biancone L PLoS One; 2020; 15(10):e0240335. PubMed ID: 33057374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]